Pms45 - Cost Per Responder Analysis Following a 48-Week Psoriatic Arthritis Treatment With Secukinumab Versus Adalimumab From the Portuguese Payer Perspective
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.1759
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV